BCRX Q3 2025 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$159M+36.1% YoY

Gross Profit

$157M98.4% margin

Operating Income

$30M18.6% margin

Net Income

$13M8.1% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

-2.4%

Cash Flow

Operating Cash Flow

$41M

Free Cash Flow

$40M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$446M

Total Liabilities

$834M

Stockholders' Equity

-$388M

Cash & Equivalents

$84M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$159M	$117M	+36.1%
Gross Profit	$157M	$114M	+37.8%
Operating Income	$30M	$8M	+284.7%
Net Income	$13M	-$14M	+191.9%

Revenue Segments

Product

$158M99%

Collaborative and Other Research and Development

$2M1%